Triligent International   Report issue

For profit Phase 2 Phase 3
Founded: Newport Beach CA United States (1996)

Organization Overview

First Clinical Trial
2012
NCT01479517
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Triligent International

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 6